卢汶,陈小燕.格列美脲联合二甲双胍或阿卡波糖治疗2型糖尿病临床对比研究.[J].中南医学科学杂志.,2019,(4):404-406, 410.
格列美脲联合二甲双胍或阿卡波糖治疗2型糖尿病临床对比研究
Clinical effect of glimepiride combined with metformin or acarbose in the treatment of type 2 diabetes mellitus
投稿时间:2018-09-07  修订日期:2019-04-12
DOI:10.15972/j.cnki.43-1509/r.2019.04.017
中文关键词:  格列美脲  阿卡波糖  二甲双胍  糖尿病
英文关键词:glimepiride  acarbose  metformin  diabetes mellitus
基金项目:
作者单位
卢汶 西电集团医院内分泌科,陕西 西安 710077 
陈小燕 西电集团医院内分泌科,陕西 西安 710077 
摘要点击次数: 532
全文下载次数: 533
中文摘要:
      本研究通过分析格列美脲联合二甲双胍或阿卡波糖治疗2型糖尿病的临床效果。对照组患者采用格列美脲联合阿卡波糖治疗,观察组患者采用格列美脲联合二甲双胍治疗。观察两组患者治疗后的血糖、胰岛功能、血脂水平以及氧化应激水平的变化。结果显示,格列美脲联合二甲双胍治疗组降糖效果明显,HOMA-IR和HOMA-β显著升高,且TG有下降的趋势, MAGE、3-NT和CRP下降明显。总体说明格列美脲联合二甲双胍治疗2型糖尿病改善患者血糖水平更有优势,并且可以显著的改善胰岛素相关指标,临床总有效率更高,好于联合阿卡波糖进行治疗。
英文摘要:
      This study focused on the clinical effects of glimepiride combined with metformin or acarbose in the treatment of type 2 diabetes.The control group was treated with glimepiride combined with acarbose, while the observation group was treated with glimepiride combined with metformin. The changes of blood sugar, islet function, lipid level and oxidative stress were observed after treatment in both groups.The results showed that the glimepiride combined with metformin treatment group had significant hypoglycemic effect, HOMA-IR and HOMA-β were significantly increased, and TG decreased, and MAGE, 3-NT and CRP decreased significantly. Overall, glimepiride combined with metformin in the treatment of type 2 diabetes has improved blood glucose levels, and it can also significantly improve insulin-related indicators, clinically more effective, which is better than combined acarbose.
查看全文  查看/发表评论  下载PDF阅读器
关闭
function PdfOpen(url){ var win="toolbar=no,location=no,directories=no,status=yes,menubar=yes,scrollbars=yes,resizable=yes"; window.open(url,"",win); } function openWin(url,w,h){ var win="toolbar=no,location=no,directories=no,status=no,menubar=no,scrollbars=yes,resizable=no,width=" + w + ",height=" + h; controlWindow=window.open(url,"",win); } &et=3C06DB566315F8DC786D8F01EA4720E07EFECA60159F12DBF21A667B351C516B4707AEB79D52E4D2A807551A26DD11FADFD24E81520E19CE4818572679C6F83A779BABDF0D71A31CEFFC92C71BEA9167AA542F7A0ADA77129C5DA3A6E0F5F1FCF83A1FF113071A16365597E94DD3DC85&pcid=A9DB1C13C87CE289EA38239A9433C9DC&cid=BB33F1C95224820A&jid=6A20DF2A798996E24F064D5ECF83A153&yid=B6351343F4791CA3&aid=C287CD5914DB95B0A32BD1BAB3A1F6D2&vid=&iid=E158A972A605785F&sid=B79ACB6EBBFC9730&eid=F7F5B5D5F4B18FC1529F5A8F5D479CF5&fileno=20190417&flag=1&is_more=0">